Compare CHCO & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHCO | AMLX |
|---|---|---|
| Founded | 1957 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 1995 | 2021 |
| Metric | CHCO | AMLX |
|---|---|---|
| Price | $139.17 | $17.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $132.50 | $21.56 |
| AVG Volume (30 Days) | 150.9K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | 13.18 | ★ 65.46 |
| EPS | ★ 2.20 | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $5.16 | N/A |
| Revenue Next Year | $3.12 | N/A |
| P/E Ratio | $61.27 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $113.21 | $7.48 |
| 52 Week High | $138.18 | $19.15 |
| Indicator | CHCO | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 66.37 | 55.31 |
| Support Level | $120.29 | $12.14 |
| Resistance Level | N/A | $18.88 |
| Average True Range (ATR) | 3.17 | 1.07 |
| MACD | 0.14 | -0.12 |
| Stochastic Oscillator | 90.23 | 57.26 |
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.